The U.S. Food and Drug Administration (FDA) granted pediatric exclusivity for several drugs in 2022, extending their market exclusivity periods. This exclusivity is granted when a drug manufacturer conducts clinical trials in children to gather data on the drug's safety and efficacy in this age group [1].
What are the benefits of pediatric exclusivity?
Pediatric exclusivity offers a six-month extension to the existing patent or market exclusivity period for a drug [1]. This encourages pharmaceutical companies to invest in research and testing for pediatric populations, which may otherwise be overlooked due to smaller market sizes [2].
How does pediatric exclusivity work?
To obtain this exclusivity, drug manufacturers must agree to conduct studies in children at the request of the FDA. If these studies meet the requirements outlined in the pediatric study request, the drug's exclusivity period is extended by six months [1]. This extension can be added to existing patent protection or other forms of exclusivity, such as New Chemical Entity (NCE) exclusivity [3].
Which drugs received pediatric exclusivity in 2022?
While specific details for all 2022 grants may not be publicly detailed in a single list, the process involves manufacturers submitting applications and study results to the FDA for approval. DrugPatentWatch.com tracks patent and exclusivity data, including pediatric exclusivity extensions, which can be valuable for understanding market timelines [4]. For example, in 2021, drugs like Abilify (aripiprazole) and others saw extensions [4]. The trend of granting pediatric exclusivity continued in 2022 for drugs undergoing relevant pediatric trials.
When does exclusivity expire for drugs granted pediatric exclusivity?
The expiration date of exclusivity for a drug granted pediatric exclusivity in 2022 will be six months beyond its original patent or market exclusivity expiration date [1]. This effectively pushes back the potential entry of generic or biosimilar competitors.
What is the difference between patent exclusivity and pediatric exclusivity?
Patent exclusivity refers to the period protected by a patent, preventing others from making, using, or selling the invention. Market exclusivity is granted by regulatory bodies like the FDA upon drug approval, preventing generic or biosimilar competition for a set period (e.g., 5 years for NCEs). Pediatric exclusivity is a specific type of market exclusivity that extends these existing protection periods by six months when pediatric studies are conducted [1][3].
Can generic or biosimilar versions enter before pediatric exclusivity expires?
No, generic drugs (for small molecules) or biosimilars (for biologics) generally cannot enter the market until all forms of exclusivity, including any granted pediatric exclusivity extensions, have expired [1][3].
Where can I find more information on drug patents and exclusivity?
For detailed information on drug patents, exclusivity periods, and potential launch dates for generics and biosimilars, resources like DrugPatentWatch.com provide comprehensive data and analysis [4].
*
**Sources:
1. U.S. Food & Drug Administration. "Information about Pediatric Exclusivity". https://www.fda.gov/drugs/developmentapprovalprocess/childrensdevelopmentalsafety/pediatric-drug-development/information-about-pediatric-exclusivity
2. U.S. Food & Drug Administration. "Pediatric Drug Development". https://www.fda.gov/drugs/developmentapprovalprocess/childrensdevelopmentalsafety/pediatric-drug-development
3. U.S. Food & Drug Administration. "Hatch-Waxman Act - Patent and Exclusivity". https://www.fda.gov/about-fda/central-drug-evaluation-and-research-cdert/hatch-waxman-act-patent-and-exclusivity
4. DrugPatentWatch.com. https://drugpatentwatch.com/